Alexion weakness would be buying opportunity, says Deutsche Bank Deutsche Bank believes any weakness in shares of Alexion from the company's FDA warning letter would be a buying opportunity. Deutsche thinks the letter will not be impactful to Soliris and points out the company has sufficient inventory on hand.
Alexion CEO Dr. Leonard Bell retired as of March 31 Dr. Leonard Bell, the principal founder and CEO of Alexion Pharmaceuticals retired from Alexion effective March 31, after serving as CEO for twenty-three years. No severance was paid to Dr. Bell in connection with his retirement. On April 1, Alexion entered into a Consulting Agreement and a Letter Agreement with Dr. Bell. Dr. Bell continues to serve as Alexion's Chairman of the Board of Directors.